The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies.

被引：16

作者：

Perez E.A. ^{[1
]}

机构：

[1] Division of Hematology/Oncology, Mayo Clinic and Mayo Foundation, 4500 San Pablo Road, Jacksonville, 32224, FL

来源：

Current Oncology Reports | 2001年 / 3卷 / 6期

关键词：

Paclitaxel; Trastuzumab; Metastatic Breast Cancer; Monoclonal Antibody Therapy; HER2 Gene Amplification;

D O I：

10.1007/s11912-001-0073-9

中图分类号：

学科分类号：

摘要：

HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive resected breast cancer is based on several factors. These include 1) the relative and absolute poor prognosis of patients with node-positive, HER2-positive breast cancer; 2) the emerging data of potential importance concerning anthracyclines as a component of adjuvant therapy for patients with HER2-positive breast cancer; 3) the role of taxanes in the management of patients with HER2-positive metastatic breast cancer; and 4) the feasibility and efficacy of molecularly targeted anti-HER2 monoclonal antibody treatment alone or in combination with chemotherapy for patients with advanced breast cancer.

引用

页码：516 / 522

页数：6

共 66 条

[1]

Pressman D(1953)The in vivo localization of anti-Wagner osteogenic sarcoma antibody Cancer 6 619-623

[2]

Korngold L(1975)Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495-497

[3]

Kohler G(1980)Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Res 40 3147-3154

[4]

Milstein C(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182

[5]

Nadler LM(1999)HER-2 as a prognostic, predictive, and therapeutic target in breast cancer Cancer Control 6 233-240

[6]

Stashenko P(2000)HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 92 1991-1998

[7]

Hardy R(2001)When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer J Clin Oncol 19 2334-2356

[8]

Slamon DJ(2000)A meta-anlysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) [abstract] Proc ASCO 19 78a-78a

[9]

Clark GM(2001)HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer [abstract] Proc ASCO 20 23a-23a

[10]

Wong SG(1999)Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639-2648

← 1 2 3 4 5 6 7 →